The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011

International Journal of Health Economics and Management

Volumn 15, Issue 3, 2015, Pages 339-359

  Lichtenberg, Frank R ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

Canada; Cancer; Chemotherapy; Innovation; Longevity; Mortality; Neoplasm; Pharmaceutical

Indexed keywords

EID: 84974602169     PISSN: 21999023     EISSN: 21999031     Source Type: Journal    
DOI: 10.1007/s10754-015-9172-2     Document Type: Article

References (24)

1. Association of Public Health Epidemiologists in Ontario. (2015). Calculating potential years of life lost (PYLL). http://www.apheo.ca/index.php?pid=190.
2. Burnet, N. G., Jefferies, S. J., Benson, R. J., Hunt, D. P., & Treasure, F. P. (2005). Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. British Journal of Cancer, 92(2), 241–245. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361853/.
3. Center for Medicare and Medicaid Services. (2013). National Health Expenditure Data. http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/tables.pdf.
4. Dorsey, E. R., et al. (2010). Financial anatomy of biomedical research, 2003–2008. Journal of the American Medical Association, 303(2), 137–143.
5. Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., & Weissert, W. G. (2000). Willingness to pay for a quality-adjusted life year. In Search of a Standard, Med Decis Making, 20(3), 332–342. http://users.phhp.ufl.edu/jharman/healthecon/Hirth%20WTP%20QALY.pdf.
6. Honoré, B. E., & Lleras-Muney, A. (2006). Bounds in competing risks models and the war on cancer. Econometrica, 74(6), 1675–1698.
7. Jalan, J., Ravallion, M. (2001). Does piped water reduce diarrhea for children in rural india? World Bank Development Research Group, Policy Research Working Paper 2664. http://www1.worldbank.org/prem/poverty/ie/dime_papers/332.pdf.
8. Law, M. R. (2013). Money Left on the Table: Generic Drug Prices in Canada. Healthcare Policy, 8(3), 17–25. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999558/#!po=44.7368/
9. Lichtenberg, F. R. (2009). The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978–2004. Economics of Innovation and New Technology, 18(5), 407–428.
10. Lichtenberg, F. R. (2014a). The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009. Economics and Human Biology, 13, 107–127.
11. Lichtenberg, F. R. (2014b). Has medical innovation reduced cancer mortality? CESifo Economic Studies, 60(1), 135–177.
12. National Cancer Institute. (2015a). Cancer screening overview. http://www.cancer.gov/cancertopics/pdq/screening/overview/patient/page5.
13. National Cancer Institute. (2015b). Drug Discovery at the National Cancer Institute. http://www.cancer.gov/cancertopics/factsheet/NCI/drugdiscovery.
14. National Cancer Institute. (2015c). Person-years of life lost. Cancer Trends Progress Report, 2009/2010 Update. http://progressreport.cancer.gov/end/life_lost.
15. National Cancer Institute. (2015d). Off-label drug use in cancer treatment. http://www.cancer.gov/about-cancer/treatment/drugs/off-label.
16. Nobelprize.org. (2015). The prize in economics 1987—Press release. http://www.nobelprize.org/nobel_prizes/economic-sciences/laureates/1987/press.html.
17. Renard, F., Tafforeau, J., & Deboosere, P. (2014). Premature mortality in Belgium in 1993–2009: Leading causes, regional disparities and 15 years change. Archives of Public Health, 72(1), 34.
18. Romer, P. (1990). Endogenous technological change. Journal of Political Economy, 98(5, Part 2), S71–S102.
19. Sampat, B. N., & Lichtenberg, F. R. (2011). What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Affairs, 30(2), 332–339.
20. Solow, R. M. (1960). Investment and technological progress. In K. Arrow, S. Karlin, & P. Suppes (Eds.), Mathematical methods in social sciences 1959 (pp. 89–104). Stanford: Stanford University Press.
21. Squires, D. A. (2011). The U.S. health system in perspective: A comparison of twelve industrialized nations. Issue brief (Commonwealth Fund), 16, 1–14. http://www.commonwealthfund.org/~/media/files/publications/issue-brief/2011/jul/1532_squires_us_hlt_sys_comparison_12_nations_intl_brief_v2.pdf.
22. Stukel T. A., Fisher E. S., Wennberg, D. E., Alter, D. A., Gottlieb, D. J., & Vermeulen, M. J. (2007). Analysis of observational studies in the presence of treatment selection bias: Effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA, 297(3), 278–285. http://jama.jamanetwork.com/article.aspx?articleid=205172.
23. U.S. Food and Drug Administration. (2015). Table of pharmacogenomic biomarkers in drug labeling. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm.
24. World Health Organization. (2015). ICD-10 Version 2015, Chapter II, Neoplasms. http://apps.who.int/classifications/icd10/browse/2015/en#/II.